Prevalence and impact of fibrinolytic dysregulation in patients with acute coronary syndromes
Open Access
- 22 May 2021
- journal article
- research article
- Published by Springer Nature in Thrombosis Journal
- Vol. 19 (1) , 1-7
Abstract
Objective: Dual antiplatelet therapy can reduce coronary thrombosis and improve the prognosis in patients with acute coronary syndrome (ACS). However, there was limited prognostic information about fibrinolytic dysregulation in patients with ACS. This study is aimed to evaluated the prevalence and impact of fibrinolytic dysregulation in patients with acute coronary syndrome (ACS). Methods: We retrospectively analyzed coagulation and fibrinolysis related indexes of ACS in hospitalized adults with rapid thrombelastography between May 2016 and December 2018. All of the follow-up visits were ended by December 2019. The primary outcome was the occurrence of major adverse cardiovascular events (MACEs), which included unstable angina pectoris, non-fatal myocardial infarction, non-fatal cerebral infarction, heart failure and all-cause death. Results: Three hundred thirty-eight patients were finally included with an average age of 62.5 ± 12.8 years old, 273 (80.5%) were males, 137(40.5%) patients were with ST-elevation myocardial infraction. Fibrinolysis shutdown (LY303.0%) were observed among 163 (48.2%) and 76(22.5%) patients, respectively. During a total of 603.2 person·years of follow-up period, 77 MACEs occurred (22.8%). Multivariate Cox regression analysis indicated that LY30 [HR: 1.101, 95% CI: 1.010–1.200, P = 0.028] was independently correlated with the occurrence of MACEs. The hazard ratios pertaining to MACEs in patients with fibrinolysis shutdown and hyperfibrinolysis compared with those in the physiologic range (LY30: 0.8–3.0%) were 1.196 [HR: 1.196, 95% CI: 0.679–2.109,P = 0.535] and 2.275 [HR: 2.275, 95% CI: 1.241–4.172, P = 0.003], respectively. Conclusions: Fibrinolytic dysregulation is very common in selected patients with ACS, and hyperfibrinolysis (LY30 > 3%) is associated with poor outcomes in patients with ACS.Keywords
All Related Versions
Funding Information
- Natural Science Foundation of Guangdong Province (2017A030313560)
This publication has 17 references indexed in Scilit:
- Prevalence and Impact of Admission Acute Traumatic Coagulopathy on Treatment Intensity, Resource Use, and Mortality: An Evaluation of 956 Severely Injured Children and AdolescentsJournal of the American College of Surgeons, 2017
- Thrombelastographic hypercoagulability and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): a randomized controlled trialPlatelets, 2017
- Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured PatientsJournal of the American College of Surgeons, 2016
- Prevalence and impact of admission hyperfibrinolysis in severely injured pediatric trauma patientsSurgery, 2015
- 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2015
- Platelet function monitoring guided antiplatelet therapy in patients receiving high-risk coronary interventions2014
- Role of Thrombelastography (TEG) in Risk Assessment and Guidance of Antithrombotic Therapy in Patients with Coronary Artery DiseaseDrug Development Research, 2013
- Admission rapid thrombelastography delivers real-time “actionable” data in pediatric traumaJournal of Pediatric Surgery, 2013
- Admission Rapid Thrombelastography Can Replace Conventional Coagulation Tests in the Emergency DepartmentAnnals of Surgery, 2012
- Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary InterventionJACC, 2007